Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.60 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | CTSC | P53634 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229345 | 1.00 | METAP2 (0.60) | METAP2MMP8CTSCOPRD1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL15258901 | 0.94 | METAP2 (0.55) | METAP2MMP8CTSCOPRD1OPRM1 | |
| SCHEMBL10645951 | 0.89 | OPRD1 (0.54) | CTSCOPRD1OPRM1OPRK1 | |
| SCHEMBL13135022 | 0.89 | MAPT (0.57) | CTSCOPRD1OPRM1OPRK1ALPI | |
| Hydrochloric Acid SCHEMBL7326138 | 0.88 | OPRD1 (0.53) | CTSCOPRD1OPRM1OPRK1 | |
| SCHEMBL21952759 | 0.88 | CTSC (0.52) | METAP2CTSCOPRD1OPRM1OPRK1 | |
| SCHEMBL5967176 | 0.88 | CTSC (0.52) | METAP2CTSCOPRD1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL5967173 | 0.86 | CTSC (0.51) | METAP2CTSCOPRD1OPRM1OPRK1 | |
| SCHEMBL29480449 | 0.86 | OPRK1 (0.57) | MMP8CTSCOPRK1 | |
| SCHEMBL27546531 | 0.85 | METAP2 (0.73) | METAP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189708-B2 | Topical composition for skin | KAO CORPORATION (JP) | 2007-03-13 | — | — | US | disclosed |
| EP-1090625-B1 | Topical composition for the skin and use thereof | KAO CORP (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20030087833-A1 | Topical composition for skin | KAO CORPORATION (JP) | 2003-05-08 | — | — | US | disclosed |
| US-6489291-B1 | Topical composition for skin | KAO CORPORATION (JP) | 2002-12-03 | — | — | US | disclosed |
| EP-1090625-A2 | Topical composition for the skin and use thereof | Kao Corporation (JP) | 2001-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087833-A1 | Topical composition for skin | CUTA, SLC38A7, CCR8 | METAP2 1157/4885MMP8 39/4885CTSC 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.